Results 21 to 30 of about 6,366 (207)

Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment

Substance Abuse Treatment, Prevention, and Policy, 2021
Background A high proportion of people receiving both oral and injectable opioid agonist treatment report concurrent use of stimulants (i.e. cocaine and or amphetamines), which has been associated with higher rates of continued illicit opioid use and ...
Heather Palis, Kirsten Marchand, Gerald “ Spike” Peachey, Jordan Westfall, Kurt Lock, Scott MacDonald, Jennifer Jun, Anna Bojanczyk-Shibata, Scott Harrison, David C. Marsh, Martin T. Schechter, Eugenia Oviedo-Joekes   +11 more
doaj   +1 more source

Temporal Patterns of Medications Dispensed to Children and Adolescents in a National Insured Population [PDF]

, 2011
This study aimed to comprehensively describe prevalence and temporal dispensing patterns for medications prescribed to children and adolescents in the United States.
A Clavenna, A Clavenna, AR Ellis, C Berg, DE May, ER Cox, H Hassanin, HS Blix, James G. Scott, JG Waxmonsky, K Hameen-Anttila, Karen L. Olson, Kenneth D. Mandl, L Christensen, L Vernacchio, M Olfson, M Olfson, M Olfson, M Tournier, O Karlstad, OM Fredheim, P Pathak, R Ackers, R Jain, S Crystal, S Karve, SH Simpson, T Lasky   +27 more
core   +16 more sources

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report

Harm Reduction Journal, 2021
Background For people with opioid use disorder who are not responding to oral opioid agonist treatment, evidence supports the effectiveness of injectable opioid agonist treatment with injectable hydromorphone (an opioid analgesic) and diacetylmorphine ...
Heather Palis, Scott MacDonald, Jennifer Jun, Eugenia Oviedo-Joekes   +3 more
doaj   +1 more source

Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system

Frontiers in Pharmacology, 2023
Background: Methylphenidate, atomoxetine, and Amphetamine are the three most commonly used medications approved by the United States Food and Drug Administration (FDA) for the treatment of attention deficit/hyperactivity disorder (ADHD).
Wei Wei, Wei Wei, Wei Wei, Li Chen, Li Chen, Hui Zhou, Hui Zhou, Jinfeng Liu, Yue Zhang, Shiyu Feng, Shiyu Feng, Shiyu Feng, Yingtao Bai, Yanen Leng, En Chang, Liang Huang, Liang Huang   +16 more
doaj   +1 more source

Psychostimulants in the Treatment of Depressive Disorders [PDF]

Psikiyatride Güncel Yaklaşımlar, 2015
Despite antidepressant therapy of appropriate trial duration and dose optimization, 50-60% of depressed patients have an adequate treatment response, whereas only 35-40% achieve remission.
Okan Ekinci, Asli Erkan Ekinci, Selahattin Bolek   +2 more
doaj   +1 more source

Nootropics use in the workplace. Psychiatric and ethical aftermath towards the new frontier of bioengineering [PDF]

, 2020
OBJECTIVE: The authors have sought to expound upon and shed a light on the rise of nootropics, which have gradually taken on a more and more relevant role in workplaces and academic settings.
Bersani, G, Ciallella, C, Del Rio, A, Marinelli, E, Rinaldi, Raffaella, Zaami, S   +5 more
core   +1 more source

A novel effective treatment for menière’s disease - dextroamphetamine sulfate

Clinical and Experimental Obstetrics & Gynecology, 2020
Purpose: To determine if treatment with dextroamphetamine sulfate could ameliorate the symptoms of long-standing Menière’s disease in a menopausal woman with a past history of dysmenorrhea.
J.H. Check, D. Check, R. Cohen
doaj   +1 more source

The Therapeutic Potential of Amphetamine-like Psychostimulants

Life, 2023
This review delves into the therapeutic applications of amphetamine-type stimulants such as lisdexamphetamine dimesylate, mixed amphetamine salts, 3,4-methylenedioxymethamphetamine (MDMA), dextroamphetamine, and phentermine.
Bruno Pires, Luana M. Rosendo, Ana Teresa Brinca, Ana Y. Simão, Mário Barroso, Tiago Rosado, Eugenia Gallardo   +6 more
doaj   +1 more source

Ginkgo biloba as an adjunct to methylphenidate in the treatment of attention deficit hyperactivity disorder in children: review of articles [PDF]

Reviews in Clinical Medicine, 2015
Attention-deficit/hyperactivity disorder is one of the most common psychiatric disorders in childhood. The medications which inhibit the reuptake of noradrenline and dopamine including psychostimulants such as methylphenidate and dextroamphetamine and ...
Paria Hebrani, Fatemeh Behdani, Hoda Jalayer   +2 more
doaj   +3 more sources

Central serous chorioretinopathy associated with Adderall (dextroamphetamine-amphetamine) and topical steroid use

American Journal of Ophthalmology Case Reports, 2022
Purpose: To report a case of central serous chorioretinopathy (CSC) associated with Adderall (dextroamphetamine-amphetamine) and topical steroid use. Observations: A 34-year-old man presented for evaluation of a “cloud” in his vision for three months. He
Joseph B. Alsberge, Daniel Y. Lee, J. Michael Jumper   +2 more
doaj   +1 more source